BF∗F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus
Tipo
Artigo
Data de publicação
2016
Periódico
Lupus
Citações (Scopus)
3
Autores
Picceli V.F.
Skare T.L.
Nisihara R.M.
Nass F.R.
Messias-Reason I.T.
Da Rosa Utiyama S.R.
Skare T.L.
Nisihara R.M.
Nass F.R.
Messias-Reason I.T.
Da Rosa Utiyama S.R.
Orientador
Título da Revista
ISSN da Revista
Título de Volume
Membros da banca
Programa
Resumo
© The Author(s) 2015.Background: B factor (BF) from the alternative complement pathway seems to participate in the pathophysiology of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Objective: To study the allotypic variability of BF in SLE and their associations with clinical and autoantibodies profile. Methods: BF allotypes were determined by high-voltage agarose gel electrophoresis, under constant cooling, followed by immunofixation with anti-human BF antibody, in 188 SLE patients and 103 controls. Clinical and serological data were obtained from medical examination and records. Results: No significant differences of BF variants between patients and controls were found, neither in relation to epidemiologic or clinical manifestations. Associations of phenotype BF SS07 and allotype BF∗S07 were found with anticardiolipin IgM (aCl-IgM) antibodies (p = 0.014 and p = 0.009 respectively), but not with aCl-IgG, lupus anticoagulant (LA), anti β2GPI or clinical APS. A significant decrease in BF∗F allotype (p = 0.043) and BF SF phenotype (p = 0.018) was detected in patients with anti-phospholipid antibodies as a whole (aCl-IgG, aCl-IgM, LA and anti β2GPI). Conclusions: There is a link between phenotype BF SS07 and allotype BF∗S07 with aCl-IgM in SLE patients; BF∗F allotype could be considered a marker of protection against the development of antiphospholipid antibodies in these patients.
Descrição
Palavras-chave
Assuntos Scopus
Adolescent , Adult , Aged , Antibodies, Anticardiolipin , Antibodies, Antiphospholipid , Antiphospholipid Syndrome , Biomarkers , Case-Control Studies , Complement Factor B , Complement Pathway, Alternative , Electrophoresis, Agar Gel , Female , Gene Frequency , Humans , Immunoglobulin M , Lupus Erythematosus, Systemic , Male , Middle Aged , Phenotype , Polymorphism, Genetic , Predictive Value of Tests , Protective Factors , Risk Factors , Young Adult